NEW YORK, Nov. 29, 2017 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of Acorda Therapeutics, Inc. ("Acorda") (NASDAQ:ACOR) between April 18, 2016 and November 14, 2017. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Southern District of New York. To get more information go to:
http://www.zlk.com/plsra-c/acorda-therapeutics-inc?wire=3
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that throughout the class period Defendants issued materially false and/or misleading statements and/or failed to disclose that: (i) the drug treatment tozadenant entailed significant undisclosed safety risks; (ii) accordingly, the Company had overstated tozadenant’s approval prospects and commercial viability; (iii) the Company had likewise overstated the benefits of the Biotie Acquisition; and (iv) as a result of the foregoing, Acorda’s shares traded at artificially inflated prices during the Class Period.
On November 15, 2017, Acorda revealed it had ceased enrolling new patients in its Phase 3 trial of its Parkinson’s treatment due to patient deaths.
If you suffered a loss in Acorda you have until January 17, 2018 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
30 Broad Street - 24th Floor
New York, NY 10004
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com


SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Anta Sports Expands Global Footprint With Strategic Puma Stake
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances
Samsung Electronics Shares Jump on HBM4 Mass Production Report
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 



